Business Context and Reporting Period
Company: BioCardia, Inc. (BCDA)
Filing Type: Form 8-K (Current Report)
Date of Report: October 28, 2024
Reporting Period: Event-specific report dated October 28, 2024.
The filing reports the completion of the last protocol-specified follow-up visit in the CardiAMP HF trial, a prospective, randomized, double-blinded, placebo procedure-controlled, multi-center pivotal clinical trial.
Key Financial Metrics
This Form 8-K does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing is strictly an event notification regarding clinical trial progress.
Material Changes
Clinical Trial Milestone: The Company announced the completion of the final follow-up visit for the CardiAMP HF pivotal trial. This marks a significant operational milestone preceding the anticipated data readout and potential regulatory submission.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) detailing the trial completion but does not include specific forward-looking guidance, financial outlook, or risk factors within the text of this 8-K summary.
Unusual Items: None reported in this specific filing text.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for details on the trial's primary endpoints and data analysis timeline.
- Confirm the expected date for the release of the CardiAMP HF trial results.
- Review subsequent filings for any updates on regulatory strategy following the trial completion.
- Check the Company's most recent 10-Q or 10-K for current cash runway and liquidity status, as this 8-K does not provide financial data.